Clinical evaluation of pulpotomy using biomtaplus and biodentine.

Evaluation of clinical performance of two calcium silicate-based materials for pulpotomy: A randomized clinical trial. - NIL

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/11/076174

Enrollment

Registered

2024-11-04

Start date

Unknown

Completion date

Unknown

Last updated

2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K029- Dental caries, unspecified Health Condition 2: K029- Dental caries, unspecified

Interventions

Intervention1: Biomtaplus: BIO MTA+ is for dental treatment as a material for filling and remineralization of root canals. Additionally, it contains hydroxyapatite which is a natural component of bone

Eligibility

Inclusion criteria

Inclusion criteria: patients who are asymptomatic/symptomatic reversible pulpitis with deep dental caries in posterior teeth close to pulp chamber and bleeding easily controlled after pulp exposure and site of exposure is large.

Exclusion criteria

Exclusion criteria: very small pulp exposure or any h/o of spontaneous pain, periapical lesion and bleeding not controlled after pulp exposure

Design outcomes

Primary

Measure	Time frame
More than 75% of patients receiving pulpotomy by the materials used in the study will be preserving the pulp vitality Timepoint: 1 year	—

Secondary

Measure	Time frame
In more the 75% patients the signs & symptoms of pulpitis such as tooth ache will be curedTimepoint: 1 YEAR	—

Countries

India

Contacts

Public ContactJanga Ravi Kumar

DRS. SUDHA & NAGESWARA RAO SIDDHARTHA INSTITUTE OF DENTAL SCIENCES

drkumarjanga@gmail.com521286

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026